Skip to main content
. 2021 May 28;27(5):317–321. doi: 10.5761/atcs.oa.20-00364

Table 1. Patients’ baseline characteristics and operative parameters.

Control group: n = 30 (%) Tolvaptan group: n = 45 (%) p-value
Age (years) 74.1 ± 7.6 73.0 ± 7.8 0.536
Body weight (kg) 59.1 ± 12.3 59.8 ± 10.7 0.805
BMI (kg/m3) 22.6 ± 3.3 23.5 ± 3.9 0.247
Sex (male) 23 (77) 31 (69) 0.459
Hypertension 21 (70) 36 (80) 0.324
Hyperlipidemia 17 (57) 28 (62) 0.631
Diabetes 7 (23) 20 (44) 0.058
LVEF (%) 58.4 ± 2.3 55.2 ± 2.3 0.378
LVEF <40% 2 (7) 10 (22) 0.158
Hemoglobin (mg/dl) 11.2 ± 0.3 11.7 ± 0.3 0.211
Albumin (mg/dl) 3.5 ± 0.1 3.7 ± 0.1 0.048
Atrial fibrillation 3 (10) 12 (27) 0.067
Serum sodium (mEq/L) 140.7 ± 4.5 139.5 ± 3.2 0.172
Serum creatinine (mg/dL) 1.46 ± 0.34 1.88 ± 0.96 0.025
eGFR (mL/min/1.73 m2) 36.1 ± 1.5 30.5 ± 1.2 0.006
CKD stage 0.132
 Stage IIIb 24 (80) 28 (62)
 Stage IV 6 (20) 13 (29)
 Stage V 0 (0) 4 (9)
Operative procedure 0.646
 CAD 7 (23) 13 (29)
 VHD 12 (40) 20 (44)
 Aortic surgery 11 (37) 12 (27)
Emergency 7 (23) 9 (20) 0.730
Operation time (min) 397 ± 19 410 ± 15 0.583
OWB (ml) 2809 ± 217 2308 ± 177 0.078

BMI: body mass index; LVEF: left ventricular ejection fraction; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; CAD: coronary artery disease; VHD: valvular heart disease; OWB: operative water balance